Recurrent hepatocellular carcinoma in liver transplant recipients: Parameters affecting time to recurrence, treatment options and survival in the sorafenib era

Tumori

Volumn 97, Issue 4, 2011, Pages 436-441

  Pfiffer, Tulio E F ^a   Seehofer, Daniel ^a   Nicolaou, Annett ^a   Neuhaus, Ruth ^a   Riess, Hanno ^a   Trappe, Ralf U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Hepatic arterial infusion; Hepatocellular carcinoma; Liver transplantation; Metastasectomy; Sorafenib

Indexed keywords

AZATHIOPRINE; FLUOROURACIL; FOLIC ACID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; SORAFENIB; YTTRIUM 90;

ADULT; ARTICLE; BONE METASTASIS; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; NAUSEA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RADIOFREQUENCY ABLATION; RECURRENT CANCER; TUMOR VOLUME; VISCERAL METASTASIS;

EID: 80053647641     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700404     Document Type: Article

References (29)

1. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg, 218: 145-151, 1993. (Pubitemid 23229140)
2. SchwartzM: Liver transplantation for hepatocellular carcinoma. Gastroenterology, 127: S268-276, 2004.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 334: 693-699, 1996. (Pubitemid 26079803)
4. Yao FY, Ferrell L, Bass NM,Watson, J, Bacchetti P, Venook A, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 33: 1394-1403, 2001. (Pubitemid 32496976)
5. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF: Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg, 239: 150-159, 2004. (Pubitemid 38176347)
6. Herrero JI, Sangro B, Pardo F, Quiroga J, Inarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J: Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl, 14: 272-278, 2008. (Pubitemid 351425478)
7. Penn I, Hammond W, Brettschneider L, Starzl TE: Malignant lymphomas in transplantation patients. Transplant Proc, 1: 106-112, 1969.
8. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-termfollow-up of 42 adult patients. Transplantation, 71: 1076-1088, 2001. (Pubitemid 32448822)
9. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet, 1: 583-587, 1984. (Pubitemid 14156511)
10. Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, KasamonY,Miller TP, Fisher RI: Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.Transplantation, 86: 215-222, 2008.
11. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD: Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg, 248: 857-862, 2008.
12. GubaM, Von Breitenbuch P, SteinbauerM, Koehl G, Flegel S, HornungM, Bruns CJ, Zuelke C, Farkas S, AnthuberM, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. NatMed, 8: 128-135, 2002. (Pubitemid 34155123)
13. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, Jauch KW, Geissler EK: Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int, 18: 89-94, 2005. (Pubitemid 41742951)
14. Schumacher G, OidtmannM, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, BahraM, Neuhaus P: Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.World J Gastroenterol, 11: 1420-1425, 2005. (Pubitemid 40468074)
15. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM: Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology, 15: 1237-1243, 2009.
16. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, SchwartzME: Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl, 10: 534-540, 2004. (Pubitemid 38443593)
17. Regalia E, Fassati LR,ValenteU, PulvirentiA,Damilano I,Dardano G,Montalto F, Coppa J,MazzaferroV: Pattern andmanagement of recurrent hepatocellular carcinoma after liver transplantation. JHepatobiliary Pancreat Surg, 5: 29-34, 1998. (Pubitemid 128662554)
18. Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J: Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol, 36: 275-280, 2010.
19. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J,Wang J, Tak WY, Pan H, Burock K, Zou J,Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10: 25-34, 2009.
20. Llovet JM, Ricci S,MazzaferroV, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M,Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359: 378-390, 2008.
21. Benckert C, Jonas S, Thelen A, Spinelli A, Schumacher G, Heise M, Langrehr J, Neuhaus P: Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. Transplant Proc, 37: 1693-1694, 2005. (Pubitemid 40790798)
22. Chen JW, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, Fawcett JW, Gow PJ, Jones RM, Jeffrey GP, House AK, Strasser SI: Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford), 11: 81-89, 2009.
23. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, GuidoM, del RioMartin J, Schiano T, Cillo U: Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl, 15: 1278-1287, 2009.
24. Jonas S, Al-Abadi H, Benckert C, Thelen A, Hippler-BenscheidM, Saribeyoglu K, Radtke B, Pratschke J, Neuhaus P: Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg, 250: 1008-1013, 2009.
25. Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH,Yu JC: Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg, 200: 252-257, 2010.
26. Wu CC, Cheng SB, Yeh DC,Wang J, P'Eng F K: Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg, 96: 1049-1057, 2009.
27. Hu RH, Lee PH, Yu SC, Dai HC, Sheu JC, Lai MY, Hsu HC, Chen DS: Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery, 120: 23-29, 1996.
28. Itamoto T, Nakahara H, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T: Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery, 141: 589-597, 2007. (Pubitemid 46628978)
29. Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY: Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol, 135: 715-722, 2009.